Edition:
United States

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

53.74USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$53.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
446,074
52-wk High
$65.51
52-wk Low
$37.27

Latest Key Developments (Source: Significant Developments)

Ionis eligible to get nearly $800 mln in milestones from deal with Janssen
Thursday, 16 Nov 2017 07:00am EST 

Nov 16 (Reuters) - Ionis Pharmaceuticals Inc -:Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen.Ionis Pharmaceuticals - licensed second orally delivered generation 2.5 antisense drug to Janssen Biotech, Inc. for which Ionis earned $5 million​.Ionis Pharmaceuticals -Janssen to now assume all global development, regulatory, commercialization responsibilities for IONIS-JBI2-2.5(RX )for GI diseases​.Ionis Pharma- ‍under global collaboration deal with Janssen, co eligible to receive nearly $800 million in regulatory, sales milestone payments, others.Ionis Pharma- ‍in addition, will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized​.Ionis Pharmaceuticals Inc - ‍IONIS-JBI1-2.5(RX), first collaboration target, was licensed to Janssen last year.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 07:00am EST 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Ionis Pharma, ‍Dynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Ionis Pharmaceuticals Inc :Ionis Pharmaceuticals Inc - co, ‍Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​.Ionis Pharmaceuticals Inc - ‍Dynacure will now assume all development and commercialization responsibilities for program​.Ionis Pharmaceuticals Inc - ‍Ionis is eligible to receive additional cash or equity of up to more than $205 million in milestone payments​.Ionis Pharmaceuticals Inc - ‍Ionis is eligible to receive royalties on future product sales of drug under this collaboration​.  Full Article

Ionis Pharmaceuticals reports Q3 earnings per share $0.00
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Ionis Pharmaceuticals Inc :Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017.Q3 earnings per share $0.00.Q3 earnings per share view $0.01 -- Thomson Reuters I/B/E/S.Ionis Pharmaceuticals Inc - ‍on track to meet its 2017 guidance​.Ionis Pharmaceuticals Inc - ‍qtrly revenue $120.9 million versus $110.9 million.Ionis Pharmaceuticals Inc - ‍projecting an increase in operating expenses for Q4 of 2017 compared to Q3 of 2017​.Q3 revenue view $117.0 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $-0.16, revenue view $438.8 million -- Thomson Reuters I/B/E/S.  Full Article

IONIS PHARMACEUTICALS TO COLLABORATE WITH SEVENTH SENSE BIOSYSTEMS
Wednesday, 18 Oct 2017 07:00am EDT 

Oct 18 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS ENTERS INTO COLLABORATION WITH SEVENTH SENSE BIOSYSTEMS TO SUPPORT DEVELOPMENT OF IMPROVED BLOOD COLLECTION AND DIAGNOSTIC DEVICE.IONIS PHARMACEUTICALS INC - ‍AS PART OF ITS COMMITMENT TO COLLABORATION, CO MADE INVESTMENT OF $2 MILLION IN 7SBIO AS PART OF A SERIES C FINANCING​.  Full Article

IONIS PHARMACEUTICALS INITIATES IONIS-MAPT RX STUDY IN PATIENTS WITH ALZHEIMER'S DISEASE
Friday, 13 Oct 2017 07:00am EDT 

Oct 13 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS INITIATES CLINICAL STUDY OF IONIS-MAPT RX IN PATIENTS WITH ALZHEIMER'S DISEASE.IONIS PHARMACEUTICALS INC - ‍IONIS EARNS $10 MILLION MILESTONE PAYMENT FROM BIOGEN​.  Full Article

Akcea and Ionis submits New Drug Application for volanesorsen to FDA
Thursday, 31 Aug 2017 07:00am EDT 

Aug 31 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce submission of new drug application for volanesorsen to the U.S. FDA.Akcea Therapeutics Inc - also on track to launch volanesorsen globally in 2018 pending approval in respective markets​.Akcea Therapeutics Inc - ‍on track to submit application for marketing authorization in Canada in September for volanesorsen​.  Full Article

Ionis earns $40 million Spinraza regulatory milestone payment from Biogen
Wednesday, 30 Aug 2017 07:00am EDT 

Aug 30 (Reuters) - Ionis Pharmaceuticals Inc :Ionis earns $40 million Spinraza regulatory milestone payment from Biogen.Ionis Pharmaceuticals Inc - ‍earned a $40 million milestone payment from Biogen associated with pricing approval of Spinraza in Japan​.  Full Article

Ionis Pharma urges shareholders to reject tender offer by TRC Capital
Thursday, 24 Aug 2017 07:00am EDT 

Aug 24 (Reuters) - Ionis Pharmaceuticals Inc :Ionis recommends shareholders reject the below-the-market mini-tender offer by TRC Capital Corporation.Received notice of unsolicited mini-tender offer by TRC Capital Corp of Ontario to purchase up to 2.5 million shares of co' stock.Recommends that stockholders do not tender their shares in response to TRC Capital's offer​.‍TRC Capital corporation to purchase up to 2.5 million shares of Ionis' common stock at a price of $44.88 per share in cash​.  Full Article

Ionis to independently advance inotersen and IONIS-FB-L Rx
Friday, 11 Aug 2017 07:00am EDT 

Aug 11 (Reuters) - Ionis Pharmaceuticals Inc :Ionis to independently advance inotersen and IONIS-FB-L Rx.Ionis Pharmaceuticals Inc - Has retained all rights to inotersen and IONIS-FB-L(Rx)..Ionis Pharmaceuticals - As part of reprioritization of pipeline and strategic review of rare diseases business, GSK declined its options on both drugs.Ionis Pharmaceuticals Inc - Plans to file for marketing authorization for inotersen this year to support a commercial launch of inotersen in 2018..Ionis Pharma- Plans to initiate first phase 2 study with IONIS-FB-L(Rx) in patients with dry amd later this year, studies in other indications in 2018.  Full Article